In:
The Clinical Respiratory Journal, Wiley, Vol. 12, No. 1 ( 2018-01), p. 269-278
Abstract:
This meta‐analysis was performed to compare the risks and benefits of combined treatment with tiotropium plus formoterol versus tiotropium alone for stable moderate‐to‐severe COPD. Methods A comprehensive search of MEDLINE, EMBASE, CINAHL, and the Cochrane Library was performed to identify randomized controlled trials (RCTs) that compared formoterol plus tiotropium to tiotropium alone in COPD patients with a duration of at least 4 weeks. The cut‐off date for the search was July 1, 2015. The odds ratio (OR) or mean difference (MD) was used to pool the results with 95% confidence intervals (CI). Results Eight randomized controlled trials were eligible for this meta‐analysis. A significant improvement was observed among patients treated with tiotropium plus formoterol compared with tiotropium alone in the following spirometric indices: mean change in trough FEV1 ( P = .02), trough FVC ( P = .007), peak FEV1 ( P 〈 .00001), and peak FVC ( P 〈 .00001). A similar result was noted for the transitional dyspnea index (TDI) (MD 1.46; 95% CI 1.07‐1.85) and a clinically significant change in TDI between the tiotropium plus formoterol and tiotropium alone groups ( P 〈 .00001). Moreover, a trend toward fewer adverse events was seen in the combination treatment group compared with the tiotropium group (OR .88; 95% CI .70‐1.11), although this difference was not statistically significant. Conclusions Compared with tiotropium alone, tiotropium in combination with formoterol improved lung function and the symptoms of dyspnea in stable moderate‐to‐severe COPD patients. Moreover, the combined treatment group tended to have fewer adverse events compared with the tiotropium treatment alone group.
Type of Medium:
Online Resource
ISSN:
1752-6981
,
1752-699X
DOI:
10.1111/crj.2018.12.issue-1
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2442214-9
